ERASCA INC (ERAS) — insider trading
Health Care · NASDAQ
ERASCA INC (ERAS) has 17 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 17 (latest 2026-06-26).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | Bristol James Arthur | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Hambleton Julie | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Casdin Alexander W. | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Multani Pratik S | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-06-26 | LIU JEAN I | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Start Valerie Denise Harding | Director | Grant / award / vesting (derivative) | 29,888 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Garner Ebun | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Garner Ebun | Officer (Chief Legal Officer) | Open-market sale | 80,000 | $16.40 | $1.31M | Form 4 |
| 2026-04-01 | Garner Ebun | Officer (Chief Legal Officer) | Option exercise / conversion | 80,000 | $1.70 | $136.0K | Form 4 |
| 2026-03-04 | Morris Shannon | Officer (Chief Medical Officer) | Open-market sale | 20,000 | $15.04 | $300.8K | Form 4 |
| 2026-03-04 | Morris Shannon | Officer (Chief Medical Officer) | Option exercise / conversion | 20,000 | $1.70 | $34.0K | Form 4 |
| 2026-01-29 | Varney Michael David | Director | Grant / award / vesting (derivative) | 96,000 | $0.00 | $0 | Form 4 |
| 2026-01-29 | Morris Shannon | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 625,000 | $0.00 | $0 | Form 4 |
| 2026-01-29 | Chacko David M. | Officer (CFO and CBO) | Grant / award / vesting (derivative) | 640,000 | $0.00 | $0 | Form 4 |
| 2026-01-29 | Lim Jonathan E | Director, Officer (Chairman & CEO), 10% owner | Grant / award / vesting (derivative) | 2,000,000 | $0.00 | $0 | Form 4 |
| 2025-12-15 | Chacko David M. | Officer (CFO and CBO) | Other acquisition or disposition | 17,793 | $1.19 | $21.3K | Form 4 |
| 2025-03-04 | Morris Shannon | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 20,000 | $0.00 | $0 | Form 4 |
Ask the chat about ERAS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ERASCA INC (ERAS).
Last updated 2026-06-26 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.